Abiraterone in mCRPC. Posters presented at: 11th European Multidisciplinary Congress on Urological Cancers (EMUC19)

Safety of Abiraterone and Enzalutamide in prostate cancer patients treated with anticoagulants

PO5. Safety of abiraterone and enzalutamide in prostate cancer patients treated with anticoagulants

C. Goena et al.

A phase 2 study of the combination of PLK1 inhibitor, onvansertib, with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer

P042. A phase 2 study of the combination of PLK1 inhibitor, onvansertib, with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer

D.J. Einstein et al.

SWITCH FROM PREDNISONE TO DEXAMETHASONE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER mCRPC) TREATED WITH ABIRATERONE ACETATE (AA) IN A MULTICENTER STUDY

P044. Switch from prednisone to dexamethasone in patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in a multicenter study

I. Rivero Belenchón et al.

Real-World Outcomes With Abiraterone Plus Prednisone or Prednisolone in Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

P045. Real-world outcomes with abiraterone plus prednisone or prednisolone in metastatic castration-resistant prostate cancer: The Prostate Cancer Registry

N. Anders Bjartell et al.

EFFECTIVENESS OF ABIRATERONE ACETATE IN ELDERLY PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL-BASED CHEMOTHERAPY

P049. Effectiveness of abiraterone acetate in elderly patients with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy

S. Abreu et al.

EFFECTIVENESS OF ABIRATERONE ACETATE IN ELDERLY CHEMOTHERAPY-NAÏVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

P050. Effectiveness of abiraterone acetate in elderly chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

S. Abreu et al.

Predictors of resistance to abiraterone acetate (AA) or enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting

P067. Predictors of resistance to abiraterone acetate (AA) or enzalutamide (ENZ) in patients with metastatic castration resistant prostate cancer (mCRPC) in the post docetaxel setting

T. Omrcen et al.

Brought to you by